TXA127 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Non-Hodgkin
Conditions
Lymphoma, Non-Hodgkin, Hodgkin Disease, Multiple Myeloma
Trial Timeline
Jun 1, 2010 → Dec 1, 2020
NCT ID
NCT01121120About TXA127 + Placebo
TXA127 + Placebo is a phase 2 stage product being developed by Constant Therapeutics for Lymphoma, Non-Hodgkin. The current trial status is terminated. This product is registered under clinical trial identifier NCT01121120. Target conditions include Lymphoma, Non-Hodgkin, Hodgkin Disease, Multiple Myeloma.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Non-Hodgkin were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04401423 | Phase 2 | Completed |
| NCT01121120 | Phase 2 | Terminated |
Competing Products
20 competing products in Lymphoma, Non-Hodgkin